CA1314483C - Stabilization of 13,14-dihydro-15-ketoprostaglandins - Google Patents

Stabilization of 13,14-dihydro-15-ketoprostaglandins

Info

Publication number
CA1314483C
CA1314483C CA000591913A CA591913A CA1314483C CA 1314483 C CA1314483 C CA 1314483C CA 000591913 A CA000591913 A CA 000591913A CA 591913 A CA591913 A CA 591913A CA 1314483 C CA1314483 C CA 1314483C
Authority
CA
Canada
Prior art keywords
dihydro
keto
ester
cyclodextrin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000591913A
Other languages
English (en)
French (fr)
Inventor
Ryuji Ueno
Sachiko Kuno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ueno Seiyaku Oyo Kenkyujo KK
Original Assignee
Ueno Seiyaku Oyo Kenkyujo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ueno Seiyaku Oyo Kenkyujo KK filed Critical Ueno Seiyaku Oyo Kenkyujo KK
Application granted granted Critical
Publication of CA1314483C publication Critical patent/CA1314483C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA000591913A 1988-02-26 1989-02-23 Stabilization of 13,14-dihydro-15-ketoprostaglandins Expired - Fee Related CA1314483C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63045622A JP2597629B2 (ja) 1988-02-26 1988-02-26 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
JP45622/1988 1988-02-26

Publications (1)

Publication Number Publication Date
CA1314483C true CA1314483C (en) 1993-03-16

Family

ID=12724473

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000591913A Expired - Fee Related CA1314483C (en) 1988-02-26 1989-02-23 Stabilization of 13,14-dihydro-15-ketoprostaglandins

Country Status (13)

Country Link
EP (1) EP0330511B1 (https=)
JP (1) JP2597629B2 (https=)
KR (1) KR970005170B1 (https=)
AT (1) ATE79260T1 (https=)
AU (1) AU612791B2 (https=)
CA (1) CA1314483C (https=)
DE (1) DE68902401T2 (https=)
ES (1) ES2044087T3 (https=)
GB (1) GB2216004A (https=)
GR (1) GR3005933T3 (https=)
NZ (1) NZ228111A (https=)
OA (1) OA09236A (https=)
ZA (1) ZA891410B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420422B1 (en) 1987-09-18 2002-07-16 Sucampo Pharmaceuticals, Inc. Ocular hypotensive agents
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
US5212200A (en) * 1987-09-18 1993-05-18 R-Tech Ueno, Ltd. Ocular hypotensive agents
DE3850676T2 (de) * 1987-09-18 1994-11-03 Ueno Seiyaku Oyo Kenkyujo Kk Hypotensive okulare Mittel.
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
DE1300150T1 (de) * 1988-09-06 2003-09-18 Pharmacia Ab, Stockholm Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
DE68928551T2 (de) * 1988-10-01 1998-04-23 Ueno Seiyaku Oyo Kenkyujo Kk Oculare hypotensive Mittel
EP0410652B1 (en) * 1989-07-27 1995-05-17 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Use of 15-keto-prostanoic acid derivatives in the manufacture of a medicament for improvement of excretion of potassium ion
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
ATE121624T1 (de) * 1989-08-09 1995-05-15 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von prostansäurederivaten zur herstellung von arzneimitteln zur verbesserung der ausscheidung von nichtprotein in die därme.
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
TW224942B (https=) * 1990-04-04 1994-06-11 Adka Ueno Kk
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU7672096A (en) 1995-06-07 1998-06-03 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US6096783A (en) * 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
US6211226B1 (en) 1998-12-17 2001-04-03 Alcon Laboratories, Inc. 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
NZ539582A (en) * 2002-10-23 2007-07-27 Sucampo Ag Prostaglandin compounds for the treatment of obesity
DE602004023106D1 (de) * 2003-11-07 2009-10-22 Senju Pharma Co Pharmazeutische zusammensetzung mit prostaglandin
EP1985298A1 (en) 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910525A (ja) * 1982-06-21 1984-01-20 Teisan Seiyaku Kk プロスタグランジンｅの安定化組成物
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1323364C (en) 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
DE3869471D1 (de) 1987-05-15 1992-04-30 Ueno Seiyaku Oyo Kenkyujo Kk Fiebersteigende zusammensetzung.
DE3850676T2 (de) 1987-09-18 1994-11-03 Ueno Seiyaku Oyo Kenkyujo Kk Hypotensive okulare Mittel.

Also Published As

Publication number Publication date
ES2044087T3 (es) 1994-01-01
DE68902401D1 (de) 1992-09-17
DE68902401T2 (de) 1992-12-10
AU3029889A (en) 1989-08-31
EP0330511A2 (en) 1989-08-30
GB8904232D0 (en) 1989-04-12
NZ228111A (en) 1991-02-26
AU612791B2 (en) 1991-07-18
KR890012654A (ko) 1989-09-18
ZA891410B (en) 1989-11-29
JPH01221317A (ja) 1989-09-04
EP0330511A3 (en) 1989-10-18
GB2216004A (en) 1989-10-04
OA09236A (en) 1992-06-30
ATE79260T1 (de) 1992-08-15
EP0330511B1 (en) 1992-08-12
KR970005170B1 (en) 1997-04-14
GR3005933T3 (https=) 1993-06-07
JP2597629B2 (ja) 1997-04-09

Similar Documents

Publication Publication Date Title
CA1314483C (en) Stabilization of 13,14-dihydro-15-ketoprostaglandins
CA1309087C (en) Cyclodextrin clathrates of carbacyclin derivatives and their use as medicinal agents
KR100260573B1 (ko) 간담즙성 질병 치료제
US4423067A (en) Carbacyclins, their preparation and use
US4925652A (en) Nitroxyl compounds, and diagnostic media based thereon useful for enhancing NmR imaging
US4479944A (en) Composition containing PGI2 analogs stabilized
US4191694A (en) Prostaglandin-I2 derivatives
CS226419B2 (en) Method of preparing 9-chloro-prostaglandine derivatives
US5004752A (en) Novel 9-haloprostaglandins, processes for their preparation, and their use as medicinal agents
JP2597649B2 (ja) 気管・気管支拡張剤
AU641436B2 (en) Emulsion of lipid containing a prostaglandin analogue
FR2482097A1 (fr) Analogues de la prostaglandine e1 et compositions pharmaceutiques les contenant
CN106620682A (zh) 一种脂质体疫苗制剂及其用途和生产IgG抗体的方法
JPH0611726B2 (ja) （５Ｅ）−１３，１４，１８，１８，１９，１９−ヘキサデヒドロ−３−オキサ−６ａ−カルバプロスタグランジン−Ｉ▲下２▼−誘導体、その製法並びに該化合物を含有する血圧降下剤
JPS6152146B2 (https=)
Skuballa et al. Chemistry of stable prostacyclin analogues: synthesis of iloprost
US20010046982A1 (en) Internal 1, 15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension
WO1989004828A1 (fr) Clathrates de cyclodextrine de derives de 5-cyano-prostacycline et leur emploi comme medicaments
US4315013A (en) Certain pyrrole analogs of prostacyclin derivatives
EP0656889B1 (de) 9-chlor-prostaglandin-ester und -amide und ihre verwendung für die herstellung von arzneimitteln
TW210287B (https=)
JPS6054933B2 (ja) プロスタグランジン及びプロスタグランジン類似化合物製剤の安定化法
AU620543B2 (en) 6-oxoprostaglandin-e derivatives, process for their production and their pharmaceutical application
CA1154442A (en) 6,9-nitrilo-prostaglandin analogues
JPS61502823A (ja) 新規カルバサイクリン、その製造方法及び該化合物の薬剤としての利用

Legal Events

Date Code Title Description
MKLA Lapsed